Pour it in fortified cereal and you've got B12 to spare
Researchers can verify a COA by checking that the lab name on the document matches a real analytical facility and that the lot number on the COA matches the lot stamped on the vial
Downstream cellular signal transduction pathways induced by HGF Compared with the untreated control of the SCLC NCI-H69 cells, HGF stimulation at 40 ng ml 1 for 7.5 min caused an induction of phosphorylation of the following phosphoprotein phosphosites (Figure 2C): adducin- [S724] (146%), adducin- [S662] (125%), CREB [S133] (143%), ERK1 [T185/Y187] (449%), ERK1/2 [T202/Y204] (558%), ERK2 [T185/Y187] (289%), MAPKK (MEK) 1/2 [S221/S225] (183%), MAPKK (MEK) 3/6 [S189/S207] (118%), RB [S612] (146%), RB1 [S780] (197%), JNK [T183/Y185] (163%), STAT3 [S727] 139%), FAK [Y576] (132%), FAK [S722] (123%), FAK [S910] (165%), p38 -MAPK [T180/Y182] (136%), and AKT1 [S473] (166%) and [T308] (207%)
Reported side effects Mild headache or fatigue typically transient during initial use Mild gastrointestinal discomfort reported in some oral formulation users Sleep disruption or irritability potential sign of overstimulation Theoretical safety concerns Critical note: Because Dihexa activates the HGF/c-Met pathway which promotes cellular growth and repair there is a theoretical concern that it could potentially stimulate unwanted cell proliferation in individuals with active cancer or high cancer risk
Calendar tracking matters
Read more about research chemical risks
